Ye, Dingwei and Kanesvaran, Ravindran and Chiong, Edmund and Lojanapiwat, Bannakij and Pu, Yeong-Shiau and Rawal, Sudhir Kumar and Aik, Ong Teng and Zeng, Hao and Chung, Byung Ha and Ashani, Md Yusoff Noor and Ohyama, Chikara and Kim, Choung Soo and Hu, Zhiquang and Tsai, Yuh-Shyan and Razack, Azad Hassan Abdul and Singh, Anildeep and Liu, Yanfang and Uemura, Hirotsugu (2024) UFO registry: final analysis of baseline data from patients with advanced prostate cancer in Asia. Therapeutic Advances in Medical Oncology, 16. p. 17588359241293393. ISSN 1758-8340, DOI https://doi.org/10.1177/17588359241293393.
Full text not available from this repository.Abstract
Background: The incidence of prostate cancer (PC) is increasing in Asian countries. The epidemiology of PC, its treatment including the use of novel therapeutic options, impacts on quality of life, and clinical outcomes of patients with PC in Asia, are not well documented.Objectives: To describe the demographic and disease features of the full cohort of patients enrolled in the United in Fight against prOstate cancer (UFO) registry.Design: The UFO registry was a multi-national, longitudinal, observational study of patients with PC presenting to participating tertiary care hospitals in eight Asian countries/regions.Methods: Patients with high-risk localized PC (HRL), non-metastatic biochemically recurrent, or metastatic PC were consecutively enrolled from September 14, 2015 until September 1, 2020 and followed for up to 5 years.Results: Among the full cohort of 3635 patients, 425 had HRL, 389 had non-metastatic biochemically recurrent, and 2821 had metastatic PC. Median follow-up time was 4.2, 4.2, and 2.6 years, respectively. At first diagnosis, the mean age ranged from 65.7 to 69.1 years, 38.5% had extra-capsular tumor extension, 34.0% had regional lymph node metastases, and 65.1% had distant metastases. Quality-of-life scores at enrollment were significantly worse in patients with metastatic disease. Decisions to start therapy were mainly driven by treatment guidelines and disease progression. The decision to discontinue hormonal therapy was often due to disease progression. Few patients received novel hormonal therapies despite their availability.Conclusion: The UFO registry provides a detailed, contemporary picture of the characteristics, treatment, and outcomes of patients with PC in Asia. There is an unmet medical need to improve access to novel agents in Asia, aiming to improve quality of life and clinical outcomes.Trial registration: Clinicaltrials.gov Identifier: NCT02546908, Registry Identifier: NOPRODPCR4001.
| Item Type: | Article |
|---|---|
| Funders: | UNSPECIFIED |
| Uncontrolled Keywords: | Asia; epidemiology; prostate cancer; quality of life; registry |
| Subjects: | R Medicine > RC Internal medicine > RC0254 Neoplasms. Tumors. Oncology (including Cancer) |
| Divisions: | Faculty of Medicine > Surgery Department |
| Depositing User: | Ms. Juhaida Abd Rahim |
| Date Deposited: | 17 Jan 2025 01:15 |
| Last Modified: | 17 Jan 2025 01:15 |
| URI: | http://eprints.um.edu.my/id/eprint/47659 |
Actions (login required)
 |
View Item |
